Exactly! There is no dilution here. We have covered that a lot. If there was we would see WAYYYYY more then just a few mill shares traded a day. Dilution would be like 50 million shares hitin in a day and that dont ever happen here.
“The Company believes that its fundamentals remain strong and is looking forward to continuing to update the marketplace regarding developments on an ongoing basis. The Company has not entered into any financing transactions that would cause shareholder dilution since the Company's 10Q was reported on November 19th, 2012.The Company has not sold any shares into the marketplace. None of the officers or directors of the Company have sold any shares into the marketplace. The officers and directors of the corporation continue to believe in the Company and its fundamentals.”
Interpreting a PR doesn’t get much easier than this. Publicly traded companies cannot lie through their SEC filings and PRs or they may face serious repercussions. With the huge potential AMBS has infront of it, logical rhetoric and a few deep breaths should ease any fears of shareholders who are unsure about dilution. Furthermore, if the company was to sell any shares in the market we would be the first to know about it via an 8k, form 3.02. This is a mandatory step for any company that wishes to sell even a small amount of shares. Read about it for yourself here: http://www.sec.gov/about/forms/form8-k.pdf and control+f or command+f “3.02” to find the section on the filing I referred to.
The outcries for dilution, IMO, have not been warranted whatsoever. Some have claimed that the .1 promissory notes some of us longs remember from a month ago are about to be sold off so the high net investors can break even. This is just plain wrong, and makes me question the motives of those trying to claim this. When AMBS secured its 2 million in private financing from Dominion Capital (original agreement available here http://finance.yahoo.com/news/amarantus-biosciences-secures-1-1-195300631.html ).
The filing clearly states that: “Amarantus issued a Convertible Promissory Note to an undisclosed institutional investor (the "Investor") in the principal amount of $600,000. The Note bears interest at the rate of ten percent (10%) per annum until paid in full and can convert into shares of the Company's common stock at a price of $0.10 per share.
Doing your proper DD will prevent yourself from being scammed out of selling your shares for less than they are worth, or buying shares that are overvalued. Do not trust what others say, you must check every fact and pull them straight from SEC filings, not message boards. I hope all investors take the time to read the 10qs, and 8ks for not only AMBS, but all their future investments as well.
News 
Market Data 
Discover 
